Granted Patent
B2
US 12,447,213 · App. 16/340,376 · Granted Oct 21, 2025
Modulation of novel immune checkpoint targets
Inventors:
Vijay K. Kuchroo (Newton, MA); Ana Carrizosa Anderson (Brookline, MA); Asaf Madi (Boston, MA); Norio Chihara (Boston, MA); Aviv Regev (Cambridge, MA); Meromit Singer (Cambridge, MA); Huiyuan Zhang (Boston, MA)
Assignees:
THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
A61K47/68A61K40/11A61K40/31A61K40/4244C07K14/7051G01N33/563G01N33/574A61K45/06A61K2239/31A61K2239/57C07K2319/02C07K2319/03G01N2333/54G01N2333/70532
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network and novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module. This critical molecular circuit underlies the expression of co-inhibitory receptors such as ILT-3 in dysfunctional T cells and identifies novel regulators of T cell dysfunction.
Claims (26)
1. A method of modulating Th17 cells in a subject, comprising:
contacting a Th17 cell with one or more modulating agents that decreases activity, function, or a combination thereof of ILT-3;
wherein the one or more modulating agents comprises an antibody comprising (i) both variable regions of ZM3.8 or (ii) an antibody comprising both variable regions of ZM4.1, or a combination of (i) and (ii).
2. The method of claim 1 , wherein modulating comprises a decrease in a Th17 T cell phenotype.
3. The method of claim 2 , wherein the Th17 T cells are shifted to a Treg phenotype.
4. The method of claim 1 , wherein modulating comprises an increase in a pathogenic Th17 T cell phenotype.
5. The method of claim 1 , wherein the one or more modulating agents promotes or inhibits binding of ILT-3 to one or more ILT3 ligands.
6. The method of claim 5 , wherein the one or more ILT3 ligands is αvβ, CD166, ANGPT1, ANGPT2, ANGPT3, ANGPT4, ANGPTL1, ANGPTL2, ANGPTL3, ANGPTL4, ANGPTL5, ANGPTL6, ANGPTL7, or ANGPTL8.
7. The method of claim 1 , wherein the one or more modulating agents inhibits binding of ILT-3 to integrin αvβ3.
8. The method of claim 2 , wherein the Th17 cells are shifted away from a Th17 phenotype.
9. The method of claim 4 , wherein the Th17 cells are shifted to a pathogenic Th17 phenotype.
10. The method of claim 1 , wherein the subject is suffering from cancer, persistent infection, or an autoimmune disease.
11. The method of claim 10 , wherein the autoimmune disease is multiple sclerosis.
12. The method of claim 1 , wherein the subject has been determined to comprise immune cells which express PDPN, PROCR, PRDM1, and c-MAF, or a combination thereof.
13. The method of claim 1 , wherein the method further comprises:
detecting T cells exhibiting an exhausted phenotype or the presence of pathogenic Th17 T cells comprising:
detecting, in a sample comprising T cells, a level of expression, activity, function or a combination thereof of:
(a) an ILT-3 gene or gene product,
(b) an angiopoietin gene or gene product,
(c) a CD166 gene or gene product, or
(d) a combination thereof, and
comparing the detected level of expression, activity, function, or a combination thereof to a reference or control, wherein a difference in the detected level relative to the reference or control indicates the presence of T cells exhibiting an exhausted phenotype or wherein a difference in the detected level relative to the reference or control indicates the presence of pathogenic Th17 T cells.
14. A method of modulating Th17 cells comprising:
contacting a Th17 cell with one or more modulating agents that decrease activity, function, or a combination thereof of ILT-3, wherein the one or more modulating agents comprises (i) an antibody comprising both variable regions of ZM3.8 or (ii) an antibody comprising both variable regions ZM4.1, or a combination of (i) and (ii).
15. A method of modulating an isolated Th17 cell or a population thereof from a subject comprising:
contacting the isolated Th17 cell or the population thereof with one or more modulating agents that decreases the activity, function, or a combination thereof of ILT-3, wherein the one or more modulating agents comprises (i) an antibody comprising both variable regions of ZM3.8 or (ii) an antibody comprising both variable regions ZM4.1, or a combination of (i) and (ii).
Assignments (5)
CONFIRMATORY LICENSE
Recorded Feb 15, 2023
From: BRIGHAM AND WOMEN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062707/0289 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 19, 2019
From: CHIHARA, NORIO
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 050086/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 13, 2019
From: REGEV, AVIV
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 049457/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 13, 2019
From: SINGER, MEROMIT
To: THE BROAD INSTITUTE, INC.
Reel/Frame 049457/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 13, 2019
From: KUCHROO, VIJAY K.; ANDERSON, ANA CARRIZOSA; MADI, ASAF; ZHANG, HUIYUAN
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 049457/0557 →
Continuity (2)
Provisional Application
62405835
· Oct 7, 2016
References Cited (400)
US 3270960A
· Phillips
· 1966
[cited by applicant]
US 3536809A
· Applezweig
· 1970
[cited by applicant]
US 3598123A
· Zaffaroni
· 1971
[cited by applicant]
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 3845770A
· Theeuwes et al.
· 1974
[cited by applicant]
US 3916899A
· Theeuwes et al.
· 1975
[cited by applicant]
US 4008719A
· Theeuwes et al.
· 1977
[cited by applicant]
US 4723958A
· Pope et al.
· 1988
[cited by applicant]
US 4747825A
· Linkie et al.
· 1988
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4948592A
· Ayer et al.
· 1990
[cited by applicant]
US 4965251A
· Stamatoyannopoulos
· 1990
[cited by applicant]
US 5059595A
· Le
· 1991
[cited by applicant]
US 5073543A
· Marshall et al.
· 1991
[cited by applicant]
US 5120548A
· Mcclelland et al.
· 1992
[cited by applicant]
US 5270163A
· Gold et al.
· 1993
[cited by applicant]
US 5354556A
· Sparks et al.
· 1994
[cited by applicant]
US 5403590A
· Forse
· 1995
[cited by applicant]
US 5543158A
· Gref et al.
· 1996
[cited by applicant]
US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5589466A
· Felgner et al.
· 1996
[cited by applicant]
US 5591767A
· Mohr et al.
· 1997
[cited by applicant]
US 5593972A
· Weiner et al.
· 1997
[cited by applicant]
US 5639476A
· Oshlack et al.
· 1997
[cited by applicant]
US 5674533A
· Santus et al.
· 1997
[cited by applicant]
US 5686281A
· Roberts
· 1997
[cited by applicant]
US 5733566A
· Lewis
· 1998
[cited by applicant]
US 5811097A
· Allison et al.
· 1998
[cited by applicant]
US 5843728A
· Seed et al.
· 1998
[cited by applicant]
US 5846946A
· Huebner et al.
· 1998
[cited by applicant]
US 5851828A
· Seed et al.
· 1998
[cited by applicant]
US 5855913A
· Hanes et al.
· 1999
[cited by applicant]
US 5858358A
· June et al.
· 1999
[cited by applicant]
US 5883223A
· Gray
· 1999
[cited by applicant]
US 5906936A
· Eshhar et al.
· 1999
[cited by applicant]
US 5912170A
· Seed et al.
· 1999
[cited by applicant]
US 5912172A
· Eshhar et al.
· 1999
[cited by applicant]
US 5985309A
· Edwards et al.
· 1999
[cited by applicant]
US 6004811A
· Seed et al.
· 1999
[cited by applicant]
US 6007845A
· Domb et al.
· 1999
[cited by applicant]
US 6040177A
· Riddell et al.
· 2000
[cited by applicant]
US 6284240B1
· Seed et al.
· 2001
[cited by applicant]
US 6352694B1
· June et al.
· 2002
[cited by applicant]
US 6392013B1
· Seed et al.
· 2002
[cited by applicant]
US 6410014B1
· Seed et al.
· 2002
[cited by applicant]
US 6489458B2
· Hackett et al.
· 2002
[cited by applicant]
US 6534055B1
· June et al.
· 2003
[cited by applicant]
US 6753162B1
· Seed et al.
· 2004
[cited by applicant]
US 6797514B2
· Berenson et al.
· 2004
[cited by applicant]
US 6867041B2
· Berenson et al.
· 2005
[cited by applicant]
US 6887466B2
· June et al.
· 2005
[cited by applicant]
US 6905680B2
· June et al.
· 2005
[cited by applicant]
US 6905681B1
· June et al.
· 2005
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 7144575B2
· June et al.
· 2006
[cited by applicant]
US 7148203B2
· Hackett et al.
· 2006
[cited by applicant]
US 7160682B2
· Hackett et al.
· 2007
[cited by applicant]
US 7175843B2
· June et al.
· 2007
[cited by applicant]
US 7232566B2
· June et al.
· 2007
[cited by applicant]
US 7259015B2
· Kingsman et al.
· 2007
[cited by applicant]
US 7303910B2
· Bebbington et al.
· 2007
[cited by applicant]
US 7351585B2
· Mitrophanous et al.
· 2008
[cited by applicant]
US 7427605B2
· Davis et al.
· 2008
[cited by applicant]
US 7572631B2
· Berenson et al.
· 2009
[cited by applicant]
US 7741465B1
· Eshhar et al.
· 2010
[cited by applicant]
US 7745651B2
· Heyes et al.
· 2010
[cited by applicant]
US 7799565B2
· Maclachlan et al.
· 2010
[cited by applicant]
US 7803397B2
· Heyes et al.
· 2010
[cited by applicant]
US 7838658B2
· Maclachlan et al.
· 2010
[cited by applicant]
US 7901708B2
· Maclachlan et al.
· 2011
[cited by applicant]
US 7915399B2
· Maclachlan et al.
· 2011
[cited by applicant]
US 7982027B2
· Maclachlan et al.
· 2011
[cited by applicant]
US 7985739B2
· Kay et al.
· 2011
[cited by applicant]
US 8034334B2
· Dudley et al.
· 2011
[cited by applicant]
US 8044019B2
· Uno et al.
· 2011
[cited by applicant]
US 8058069B2
· Yaworski et al.
· 2011
[cited by applicant]
US 8088379B2
· Robbins et al.
· 2012
[cited by applicant]
US 8101741B2
· Maclachlan et al.
· 2012
[cited by applicant]
US 8188263B2
· Maclachlan et al.
· 2012
[cited by applicant]
US 8211422B2
· Eshhar et al.
· 2012
[cited by applicant]
US 8227432B2
· Hackett et al.
· 2012
[cited by applicant]
US 8236943B2
· Lee et al.
· 2012
[cited by applicant]
US 8283333B2
· Yaworski et al.
· 2012
[cited by applicant]
US 8372951B2
· Chang et al.
· 2013
[cited by applicant]
US 8399645B2
· Campana et al.
· 2013
[cited by applicant]
US 8404658B2
· Hajjar et al.
· 2013
[cited by applicant]
US 8454972B2
· Nabel et al.
· 2013
[cited by applicant]
US 8575305B2
· Gait et al.
· 2013
[cited by applicant]
US 8614194B1
· Chen et al.
· 2013
[cited by applicant]
US 8637307B2
· June et al.
· 2014
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8697854B2
· Schendel et al.
· 2014
[cited by applicant]
US 8709843B2
· Shakuda
· 2014
[cited by applicant]
US 8771945B1
· Zhang
· 2014
[cited by applicant]
US 8795965B2
· Zhang
· 2014
[cited by applicant]
US 8865406B2
· Zhang et al.
· 2014
[cited by applicant]
US 8871445B2
· Cong et al.
· 2014
[cited by applicant]
US 8889356B2
· Zhang
· 2014
[cited by applicant]
US 8889418B2
· Zhang et al.
· 2014
[cited by applicant]
US 8895308B1
· Zhang et al.
· 2014
[cited by applicant]
US 8906616B2
· Zhang et al.
· 2014
[cited by applicant]
US 8906682B2
· June et al.
· 2014
[cited by applicant]
US 8911993B2
· June et al.
· 2014
[cited by applicant]
US 8916381B1
· June et al.
· 2014
[cited by applicant]
US 8932814B2
· Cong et al.
· 2015
[cited by applicant]
US 8945839B2
· Zhang
· 2015
[cited by applicant]
US 8975071B1
· June et al.
· 2015
[cited by applicant]
US 8993233B2
· Zhang et al.
· 2015
[cited by applicant]
US 8999641B2
· Zhang et al.
· 2015
[cited by applicant]
US 9101584B2
· June et al.
· 2015
[cited by applicant]
US 9102760B2
· June et al.
· 2015
[cited by applicant]
US 9102761B2
· June et al.
· 2015
[cited by applicant]
US 9181527B2
· Sentman
· 2015
[cited by applicant]
US 9233125B2
· Davila et al.
· 2016
[cited by applicant]
US 20040171156A1
· Hartley et al.
· 2004
[cited by applicant]
US 20040224402A1
· Bonyhadi et al.
· 2004
[cited by applicant]
US 20050019923A1
· Uchegbu et al.
· 2005
[cited by applicant]
US 20060281180A1
· Radcliffe et al.
· 2006
[cited by applicant]
US 20070025970A1
· Kingsman et al.
· 2007
[cited by applicant]
US 20070054961A1
· Maden et al.
· 2007
[cited by applicant]
US 20080152654A1
· Reich
· 2008
[cited by applicant]
US 20080267903A1
· Uchegbu et al.
· 2008
[cited by applicant]
US 20090007284A1
· Radcliffe et al.
· 2009
[cited by applicant]
US 20090017543A1
· Wilkes et al.
· 2009
[cited by applicant]
US 20090111106A1
· Mitrophanous et al.
· 2009
[cited by applicant]
US 20100317109A1
· Maden et al.
· 2010
[cited by applicant]
US 20110117189A1
· Mazzone et al.
· 2011
[cited by applicant]
US 20110293571A1
· Widdowson et al.
· 2011
[cited by applicant]
US 20120244133A1
· Rosenberg et al.
· 2012
[cited by applicant]
US 20120295960A1
· Palfi et al.
· 2012
[cited by applicant]
US 20130071414A1
· Dotti et al.
· 2013
[cited by applicant]
US 20130236946A1
· Gouble
· 2013
[cited by applicant]
US 20130244279A1
· De Fougerolles et al.
· 2013
[cited by applicant]
US 20130245107A1
· De Fougerolles et al.
· 2013
[cited by applicant]
US 20140170753A1
· Zhang
· 2014
[cited by applicant]
US 20140179770A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186843A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186919A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140189896A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140242664A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140242699A1
· Zhang
· 2014
[cited by applicant]
US 20140310830A1
· Zhang et al.
· 2014
[cited by applicant]
US 20150247150A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150368342A1
· Wu et al.
· 2015
[cited by applicant]
US 20150368360A1
· Liang et al.
· 2015
[cited by applicant]
US 20160166613A1
· Spencer et al.
· 2016
[cited by applicant]
US 20160175359A1
· Spencer et al.
· 2016
[cited by applicant]
AU 2015101792A4
· 2016
[cited by applicant]
AU 2014361834A1
· 2016
[cited by applicant]
EP 1519714A1
· 2005
[cited by applicant]
EP 1766035B1
· 2011
[cited by applicant]
EP 1781593B1
· 2011
[cited by applicant]
EP 1664316B1
· 2012
[cited by applicant]
EP 2771468B1
· 2015
[cited by applicant]
EP 2784162B1
· 2015
[cited by applicant]
EP 2764103B1
· 2015
[cited by applicant]
JP 6625971B2
· 2016
[cited by applicant]
KR 20150105633A
· 2015
[cited by applicant]
KR 20160089527A
· 2016
[cited by applicant]
WO 9215322A1
· 1992
[cited by applicant]
WO 9402595A1
· 1994
[cited by applicant]
WO 9640281A2
· 1996
[cited by applicant]
WO 03020763A2
· 2003
[cited by applicant]
WO 03057171A2
· 2003
[cited by applicant]
WO 2004033685A1
· 2004
[cited by applicant]
WO 2004044004A2
· 2004
[cited by applicant]
WO 2004074322A1
· 2004
[cited by applicant]
WO 2005113595A2
· 2005
[cited by applicant]
WO 2005114215A2
· 2005
[cited by applicant]
WO 2006000830A2
· 2006
[cited by applicant]
WO 2006007712A1
· 2006
[cited by applicant]
WO 2006125962A2
· 2006
[cited by applicant]
WO 2008038002A2
· 2008
[cited by applicant]
WO 2008039818A2
· 2008
[cited by applicant]
WO 2011146862A1
· 2011
[cited by applicant]
WO 2012048265A2
· 2012
[cited by applicant]
WO 2012079000A1
· 2012
[cited by applicant]
WO 2012135025A2
· 2012
[cited by applicant]
WO 2013033734A1
· 2013
[cited by applicant]
WO 2013039889A1
· 2013
[cited by applicant]
WO 2013040371A2
· 2013
[cited by applicant]
WO 2013044225A1
· 2013
[cited by applicant]
WO 2013166321A1
· 2013
[cited by applicant]
WO 2013176915A1
· 2013
[cited by applicant]
WO 2014011987A1
· 2014
[cited by applicant]
WO 2014018423A2
· 2014
[cited by applicant]
WO 2014018863A1
· 2014
[cited by applicant]
WO 2014059173A2
· 2014
[cited by applicant]
WO 2014070874A1
· 2014
[cited by applicant]
WO 2014083173A1
· 2014
[cited by applicant]
WO 2014093595A1
· 2014
[cited by applicant]
WO 2014093622A2
· 2014
[cited by applicant]
WO 2014093635A1
· 2014
[cited by applicant]
WO 2014093655A2
· 2014
[cited by applicant]
WO 2014093661A2
· 2014
[cited by applicant]
WO 2014093694A1
· 2014
[cited by applicant]
WO 2014093701A1
· 2014
[cited by applicant]
WO 2014093709A1
· 2014
[cited by applicant]
WO 2014093712A1
· 2014
[cited by applicant]
WO 2014093718A1
· 2014
[cited by applicant]
WO 2014133567A1
· 2014
[cited by applicant]
WO 2014133568A1
· 2014
[cited by applicant]
WO 2014134165A1
· 2014
[cited by applicant]
WO 2014134351A2
· 2014
[cited by applicant]
WO 2014145631A1
· 2014
[cited by applicant]
WO 2014172606A1
· 2014
[cited by applicant]
WO 2014184744A1
· 2014
[cited by applicant]
WO 2014191128A1
· 2014
[cited by applicant]
WO 2014204723A1
· 2014
[cited by applicant]
WO 2014204724A1
· 2014
[cited by applicant]
WO 2014204725A1
· 2014
[cited by applicant]
WO 2014204726A1
· 2014
[cited by applicant]
WO 2014204727A1
· 2014
[cited by applicant]
WO 2014204728A1
· 2014
[cited by applicant]
WO 2014204729A1
· 2014
[cited by applicant]
WO 2015057834A1
· 2015
[cited by applicant]
WO 2015057852A1
· 2015
[cited by applicant]
WO 2015065964A1
· 2015
[cited by applicant]
WO 2015089351A1
· 2015
[cited by applicant]
WO 2015089364A1
· 2015
[cited by applicant]
WO 2015089419A2
· 2015
[cited by applicant]
WO 201589427A1
· 2015
[cited by applicant]
WO 201589462A1
· 2015
[cited by applicant]
WO 2015089465A1
· 2015
[cited by applicant]
WO 2015089486A2
· 2015
[cited by applicant]
WO 2015130968A2
· 2015
[cited by applicant]
WO 2016000304A1
· 2016
[cited by applicant]
WO 2016011210A2
· 2016
[cited by applicant]
WO 2016028682A1
· 2016
[cited by applicant]
WO 2016049024A2
· 2016
[cited by applicant]
WO 2016049163A2
· 2016
[cited by applicant]
WO 2016049258A2
· 2016
[cited by applicant]
WO 2016061456A2
· 2016
[cited by applicant]
WO 2016070061A1
· 2016
[cited by applicant]
WO 2016094867A1
· 2016
[cited by applicant]
WO 2016094872A1
· 2016
[cited by applicant]
WO 2016094880A1
· 2016
[cited by applicant]
WO 2016100974A1
· 2016
[cited by applicant]
WO 2016106236A1
· 2016
[cited by applicant]
WO 2016106244A1
· 2016
[cited by applicant]
WO 2016138488A2
· 2016
[cited by applicant]
WO WO2016144728A2
· 2016
[cited by examiner]
WO WO2017015227A1
· 2017
[cited by examiner]
WO WO2017069958A2
· 2017
[cited by examiner]
WO 2018067991A1
· 2018
[cited by applicant]
Rudikoff et al. (PNAS USA, 1982, 79: 1979-1983) (Year: 1982).
[cited by examiner]
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36) (Year: 1994).
[cited by examiner]
Burgess et al. (J of Cell Bio. 111:2129-2138, 1990) (Year: 1990).
[cited by examiner]
Ibragimova and Wade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198) (Year: 1999).
[cited by examiner]
Kim-Schulze et al. (J. Immunology 2006, 176: 2790-2798) (Year: 2006).
[cited by examiner]
Van den Broek et al. (Nature Reviews Immunology Jun. 2018 18:363-373) (Year: 2018).
[cited by examiner]
Moore et al. (Cancer Immunology and Immunotherapy 2009 58: 719-728) (Year: 2009).
[cited by examiner]
Invitrogen (CD85k (ILT3) Monoclonal Antibody (ZM4.1), Functional Grade, eBioscience™ 2018) (Year: 2018).
[cited by examiner]
Almagro & Fransson, Frontiers in Bioscience 2008; 13:1619-33 (Year: 2008).
[cited by examiner]
The Brigham and Women's Hospital, Inc., International Preliminary Report on Patentability issued in International Application No. PCT/US2017/055625, mailed on Apr. 18, 2019, 15 pages.
[cited by applicant]
The Brigham and Women's Hospital, Inc., International Search Report and Written Opinion issued in International Application No. PCT/US2017/055625, mailed on Mar. 26, 2018, 23 pages.
[cited by applicant]
Ahmad et al., “In Silico Modelling of Drug-Polymer Interactions for Pharmaceutical Formulations”, Journal of the Royal Society Interface, vol. 7, Issue Suppl_4, Jun. 2, 2010, S423-S433.
[cited by applicant]
Aigner, A., “Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo”, Journal of Biomedicine and Biotechnology, vol. 2006, No. 4, Article ID 71659, 2006, 16 pages.
[cited by applicant]
Akaneya et al., “RNAi-Induced Gene Silencing by Local Electroporation in Targeting Brain Region”, Journal of Neurophysiology, vol. 93, No. 1, Jan. 2005, 594-602.
[cited by applicant]
Akhtar et al., “Cellular Uptake and Intracellular Fate of Antisense Oligonucleotides”, Trends Cell Biology, vol. 2, No. 5, May 1992, 139-144.
[cited by applicant]
Akinc et al., “A Combinatorial Library of Lipid-like Materials for Delivery of RNAi Therapeutics”, Nature Biotechnology, vol. 26, Issue 5, May 2008, 20 pages.
[cited by applicant]
Alabi et al., “Multiparametric Approach for the Evaluation of Lipid Nanoparticles for siRNA Delivery”, Proceedings of the National Academy of Sciences, vol. 110, No. 32, Jul. 23, 2013, 12881-12886.
[cited by applicant]
Alhasan, Alih. , “Exosome Encased Spherical Nucleic Acid Gold Nanoparticle Conjugates As Potent MicroRNA Regulation Agents”, Small, vol. 10, Issue 1, Jan. 15, 2014, 14 pages.
[cited by applicant]
Altman et al., “Phenotypic Analysis of Antigen-specific T Lymphocytes”, Science, vol. 274, No. 5284, Oct. 4, 1996, 94-96.
[cited by applicant]
Alvarez, R.H. , “Present and Future Evolution of Advanced Breast Cancer Therapy”, Breast Cancer Research, vol. 12 ,Suppl. 2, 2010, 18 pages.
[cited by applicant]
Alvarez-Erviti et al., “Delivery of siRNA to The Mouse Brain by Systemic Injection of Targeted Exosomes”, Nature Biotechnology, vol. 29, No. 4, Apr. 2011, 9 pages.
[cited by applicant]
Anders et al., “Differential Expression Analysis for Sequence Count Data”, Genome Biology, vol. 11, No. 10, Oct. 27, 2010, 12 pages.
[cited by applicant]
Andersen et al., “Parallel Detection of Antigen-specific T Cell Responses by Combinatorial Encoding of MHC Multimers”, Nature Protocols, vol. 7, No. 5, Apr. 12, 2012, 891-902.
[cited by applicant]
Anderson et al., “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation”, Immunity, vol. 44, No. 5, May 17, 2016, 989-1004.
[cited by applicant]
Apetoh et al., “The Aryl Hydrocarbon Receptor Interacts with c-Maf to Promote the Differentiation of type 1 Regulatory T Cells Induced by IL-27”, Nature Immunology, vol. 11, No. 9, Sep. 2010, 854-861.
[cited by applicant]
Arnold et al., “Specific Beta-Adrenergic Receptor Silencing with Small Interfering RNA Lowers High Blood Pressure and Improves Cardiac Function in Myocardial Ischemia”, Journal of Hypertension, vol. 25, No. 1, Jan. 2007…
[cited by applicant]
Awasthi et al., “A Dominant Function for Interleukin 27 in Generating Interleukin 10-producing Anti-inflammatory T cells”, Nature Immunology, vol. 8, No. 12, Dec. 2007, 1380-1389.
[cited by applicant]
Balagaan et al., “Stable and Efficient Intraocular Gene Transfer Using Pseudotyped EIAV Lentiviral Vectors”, The Journal of Gene Medicine, vol. 8, Issue 3, Mar. 2006, 275-285.
[cited by applicant]
Barber et al., “Restoring Function in Exhausted CD8 T Cells During Chronic Viral Infection”, Nature, vol. 439, No. 7077, Feb. 9, 2006, 682-687.
[cited by applicant]
Bartlett et al., “Impact of Tumor-Specific Targeting on The Biodistribution and Efficacy of Sima Nanoparticles Measured by Multimodality In Vivo Imaging”, Proceedings of the National Academy of Sciences, vol. 104, No. 3…
[cited by applicant]
Bartunek et al., “Avian Stem Cell factor (SCF): Production and Characterization of the Recombinant His-tagged SCF of Chicken and its Neutralizing Antibody”, Cytokine, vol. 8, No. 1, Jan. 1996, 14-20.
[cited by applicant]
Batten et al., “Cutting Edge: IL-27 is a Potent Inducer of IL-10 but not FoxP3 in Murine T Cells”, The Journal of Immunology, vol. 180, No. 5, Mar. 1, 2008, 2752-2756.
[cited by applicant]
Bendall et al., “Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum”, Science, vol. 332, No. 6030, May 6, 2011, 23 pages.
[cited by applicant]
Besser et al., “Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients”, Clinical Cancer Research, vol. 16, No. 9, May 2010, …
[cited by applicant]
Binley et al., “Safety and Biodistribution of an Equine Infectious Anemia Virus-Based Gene Therapy, RetinoStat(®), for Age-Related Macular Degeneration”, Human Gene Therapy, vol. 23, No. 9, Sep. 2012, 980-991.
[cited by applicant]
Binz et al., “Engineering Novel Binding Proteins from Nonimmunoglobulin Domains”, Nature Biotechnology, vol. 23, No. 10, Oct. 6, 2005, 1257-1268.
[cited by applicant]
Bitko et al., “Inhibition of Respiratory Viruses by Nasally Administered siRNA”, Nature Medicine, vol. 11, Dec. 26, 2004, 50-55.
[cited by applicant]
Blackburn et al., “Coregulation of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors During Chronic Viral Infection”, Nature Immunology, vol. 10, No. 1, Jan. 2009, 23 pages.
[cited by applicant]
Blaschitz et al., “Th17 Cytokines and The Gut Mucosal Barrier”, Journal of Clinical Immunology, vol. 30, No. 2, Mar. 2010, 196-203.
[cited by applicant]
Boch et al., “Breaking the Code of DNA Binding Specificity of TAL-type III Effectors”, Science, vol. 326, No. 5959, Dec. 11, 2009, 1509-1512.
[cited by applicant]
Boni et al., “Adoptive Transfer of Allogeneic Tumor-Specific T Cells Mediates Effective Regression of Large Tumors Across Major Histocompatibility Barriers”, Blood, vol. 112, No. 12, Dec. 1, 2008, 4746-4754.
[cited by applicant]
Bonnet et al., “Systemic Delivery of DNA or siRNA Mediated by Linear Polyethylenimine (L-Pei) Does Not Induce an Inflammatory Response”, Pharmaceutical Research, vol. 25, No. 12, Aug. 16, 2008, 2972-2982.
[cited by applicant]
Buddee et al., “Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma”, PLOS One, vol. 8, Issue 12, Dec. 17…
[cited by applicant]
Burton et al., “Sequential Transcriptional Changes Dictate Safe and Effective Antigen-specific Immunotherapy”, Nature Communications, vol. 5, No. 4741, Sep. 3, 2014, 13 pages.
[cited by applicant]
Capaldi et al., “Structure and Function of a Transcriptional Network Activated by the MAPK Hog1”, Nature Genetics, vol. 40, No. 11, Nov. 2008, 18 pages.
[cited by applicant]
Carlson et al., “Identification of Amino Acids in the Glutamate Receptor, GluR3, Important for Antibody-binding and Receptor-specific Activation”, Journal of Biological Chemistry, vol. 272, No. 17, Apr. 25, 1997, 11295-…
[cited by applicant]
Castellino et al., “Mice with a Severe Deficiency of the Endothelial Protein C Receptor Gene Develop, Survive, and Reproduce Normally, and Do not Present with Enhanced Arterial Thrombosis after Challenge”, Thrombosis an…
[cited by applicant]
Cella et al., “A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing”, Journal of Experimental Medicine, vol. 185, No. 10, May 19, 1997, 1743-1751.
[cited by applicant]
Chen et al., “Genome-Wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis”, Cell, vol. 160, No. 6, Mar. 12, 2015, 28 pages.
[cited by applicant]
Cheng et al., “Crystal Structure of Leukocyte Lg-like Receptor LILRB4 (ILT3/LIR-5/CD85k): A Myeloid Inhibitory Receptor Involved in Immune Tolerance”, Journal of Biological Chemistry, vol. 286, No. 20, May 20, 2011, 180…
[cited by applicant]
Chien et al., “Novel Cationic Cardiolipin Analogue-Based Liposome for Efficient DNA and Small Interfering RNA Delivery In Vitro and In Vivo”, Cancer Gene Therapy, vol. 12, Dec. 3, 2004, 321-328.
[cited by applicant]
Cho et al., “Lipid-like Nanoparticles for Small Interfering RNA Delivery to Endothelial Cells”, Advanced Functional Materials, vol. 19, Issue 19, Oct. 9, 2009, 15 pages.
[cited by applicant]
Choi et al., “Mechanism for the Endocytosis of Spherical Nucleic Acid Nanoparticle Conjugates”, Proceedings of the National Academy of Sciences, vol. 110, No. 19, 2013, 6 pages.
[cited by applicant]
Ciofani et al., “A Validated Regulatory Network for Th17 Cell Specification”, Cell, vol. 151, Oct. 12, 2012, 289-303.
[cited by applicant]
Coelho et al., “Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis”, The New England Journal of Medicine, vol. 369, No. 9, Aug. 29, 2013, 819-829.
[cited by applicant]
Cong et al., “Multiplex Genome Engineering Using CRISPR/Cas Systems”, Science, vol. 339, No. 6121, Feb. 15, 2013, 6 pages.
[cited by applicant]
Creixell et al., “Pathway and Network Analysis of Cancer Genomes”, Nature Methods, vol. 12, No. 7, Jul. 2015, 16 pages.
[cited by applicant]
Cronican et al., “A Class of Human Proteins That Deliver Functional Proteins Into Mammalian Cells In Vitro and In Vivo”, Chemistry & Biology, vol. 18, Issue 7, Jul. 29, 2011, 10 pages.
[cited by applicant]
Cronican et al., “Potent Delivery of Functional Proteins into Mammalian Cells in Vitro and in Vivo Using a Supercharged Protein”, ACS Chemical Biology, vol. 5, No. 8, 2010, 747-752.
[cited by applicant]
Zou et al., “Intrathecal Lentiviral-Mediated RNA Interference Targeting PKCy Attenuates Chronic Constriction Injury-Induced Neuropathic Pain in Rats”, Human Gene Therapy, vol. 22, Apr. 2011, 465-475.
[cited by applicant]
Cutler et al., “Polyvalent Nucleic Acid Nanostructures”, Journal of the American Chemical Society, vol. 133, Issue 24, Jun. 22, 2011, 10 pages.
[cited by applicant]
Cutler et al., “Spherical Nucleic Acids”, Journal of the American Chemical Society, vol. 134, Issue 3, 2012, 1376-1391.
[cited by applicant]
Dahlman et al., “In Vivo Endothelial Sirna Delivery Using Polymeric Nanoparticles with Low Molecular Weight”, Nature Nanotechnology, vol. 9, No. 8, Aug. 2014, 17 pages.
[cited by applicant]
Davis et al., “Evidence of RNAi in Humans From Systemically Administered siRNA via Targeted Nanoparticles”, Nature, vol. 464, No. 7291, Apr. 15, 2010, 1067-1070.
[cited by applicant]
Davis et al., “GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor”, Bioinformatics, vol. 23, No. 14, 2007, 1846-1847.
[cited by applicant]
Di Stasi et al., “Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy”, The New England Journal of Medicine, vol. 365, No. 18, Nov. 3, 2011, 16 pages.
[cited by applicant]
Digiusto et al., “RNA-Based Gene Therapy for HIV with Lentiviral Vector-Modified CD34(+) Cells in Patients Undergoing Transplantation for AIDSrelated Lymphoma”, Science Translational Medicine, vol. 2, Issue 36, Jun. 16,…
[cited by applicant]
Diveu et al., “IL-27 Blocks RORc Expression to Inhibit Lineage Commitment of Th17 Cells”, Journal of Immunology, vol. 182, No. 9, May 1, 2009, 5748-5756.
[cited by applicant]
Doench et al., “Rational Design of Highly Active SgRNAs for CRISPR-Cas9-Mediated Gene Inactivation”, Nature Biotechnology, vol. 32, No. 12, Dec. 2014, 17 pages.
[cited by applicant]
Doering et al., “Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T cell Exhaustion versus Memory”, Immunity, vol. 37, No. 6, Dec. 2012, 1130-1144.
[cited by applicant]
Dorn et al., “siRNA Relieves Chronic Neuropathic Pain”, Nucleic Acids Research, vol. 32, No. 5, Mar. 16, 2004, 6 pages.
[cited by applicant]
Doyon et al., “Enhancing Zinc-Finger-Nuclease Activity With Improved Obligate Heterodimeric Architectures”, Nature Methods, vol. 8, No. 1, Jan. 2011, 74-79.
[cited by applicant]
Dudley et al., “Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma”, Journal of Clinical Oncology, vol. 23, No. …
[cited by applicant]
Dudley et al., “Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes”, Science, vol. 298, No. 55494, Nov. 2002, 10 pages.
[cited by applicant]
Dumitrache et al., “Trex2 Enables Spontaneous Sister Chromatid Exchanges Without Facilitating DNA Double-Strand Break Repair”, Genetics, vol. 188, No. 4, Aug. 2011, 787-797.
[cited by applicant]
El-Andaloussi et al., “Exosome-Mediated Delivery of siRNA in Vitro and in Vivo”, Nature Protocols, vol. 7, Issue 12, Dec. 2012, 2112-2126.
[cited by applicant]
Farsaci et al., “Consequence of Dose Scheduling of Sunitinib on Host Immune Response Elements and Vaccine Combination Therapy”, International Journal of Cancer, vol. 30, No. 8, Apr. 15, 2012, 19 pages.
[cited by applicant]
Finke et al., “Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients”, Clinical Cancer Research, vol. 14, No. 20, Oct. 15, 2008, 6674-6682.
[cited by applicant]
Fitzgerald et al., “Corrigendum: Suppression of Autoimmune Inflammation of the Central Nervous System by Interleukin 10 Secreted by Interleukin 27-Stimulated T Cells”, Nature Immunology, vol. 8, Nov. 28, 2007, 1372-1379.
[cited by applicant]
Fitzgerald et al., “Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis”, The Journal of Immunology, vol. 179, Issue 5, Sep. 1, 2007, 3268-3275.
[cited by applicant]
Fourcade et al., “PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines”, Cancer Research, vol. 74, Issue 4, Dec. 16, 2013, 1045-1055.
[cited by applicant]
Frederick et al., “BRAF Inhibition is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma”, Clinical Cancer Research, vol. 19, No. 5, Mar…
[cited by applicant]
Gao et al., “Non-viral Methods for siRNA Delivery”, Molecular Pharmaceutics, vol. 6, No. 3, Jun. 1, 2009, 13 pages.
[cited by applicant]
Garrett et al., “Exploring Uptake Mechanisms of Oral Nanomedicines using Multimodal Nonlinear Optical Microscopy”, Journal of Biophotonics, vol. 5, Issue 5-6, May 2012, 458-468.
[cited by applicant]
Garrett et al., “Label-Free Imaging of Polymeric Nanomedicines using Coherent Anti-Stokes Raman Scattering Microscopy”, Journal of Raman Spectroscopy, vol. 43, Issue 5, May 2012, 681-688.
[cited by applicant]
Gaublomme et al., “Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity”, Cell, vol. 163, No. 6, Dec. 3, 2015, 24 pages.
[cited by applicant]
Kuchroo, Invitation to pay Additional Fees issued in International Application No. PCT/US2017/055625, mailed on Jan. 31, 2018, 21 pages.
[cited by applicant]
Gebauer et al., “Engineered Protein Scaffolds as next-Generation Antibody Therapeutics”, Current Opinion in Chemical Biology, vol. 13, No. 3, Jun. 2009, 245-255.
[cited by applicant]
Geisbert et al., “Postexposure Protection of Non-Human Primates Against a Lethal Ebola Virus Challenge with RNA Interference: A Proof-of-Concept Study”, The Lancet, vol. 375, Issue 9729, May 29-Jun. 4, 2010, 1896-1905.
[cited by applicant]
Ghiringhelli et al., “Metronomic Cyclophosphamide Regimen Selectively Depletes CD4+CD25+ Regulatory T Cells and Restores T and NK Effector Functions In End Stage Cancer Patients”, Cancer Immunology, Immunotherapy, vol. …
[cited by applicant]
Ghoreschi et al., “Generation of Pathogenic T(H)17 Cells in the Absence of TGF-β Signalling”, Nature, vol. 467, No. 7318, Oct. 21, 2010, 14 pages.
[cited by applicant]
Gill et al., “Biopharmaceutical Drug Discovery Using Novel Protein Scaffolds”, Current Opinion in Biotechnology, vol. 17, No. 6, Dec. 2006, 653-658.
[cited by applicant]
Giordano et al., “Molecular Profiling of CD8 T Cells In Autochthonous Melanoma Identifies Maf As Driver of Exhaustion”, European Molecular Biology Organization Journal, vol. 34, No. 15, Jul. 2, 2015, 2042-2058.
[cited by applicant]
Greco et al., “Improving the Safety of Cell Therapy with the TK-Suicide Gene”, Frontiers in Pharmacology, vol. 6, No. 95, May 5, 2015, 13 pages.
[cited by applicant]
Gubin et al., “Checkpoint Blockade Cancer Immunotherapy Targets Tumour-specific Mutant Antigens”, Nature, vol. 515, No. 7528, Nov. 27, 2014, 18 pages.
[cited by applicant]
Hall et al., “The Cytokines Interleukin 27 and Interferon-γ Promote Distinct Treg Cell Populations Required to Limit Infection-Induced Pathology”, Immunity, vol. 37, No. 3, Sep. 21, 2012, 511-523.
[cited by applicant]
Hamid et al., “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma”, The New England Journal of Medicine, vol. 369, No. 2, Jul. 11, 2013, 134-144.
[cited by applicant]
Hao et al., “Nucleic Acid-Gold Nanoparticle Conjugates as Mimics of microRNA”, Small, vol. 7, Issue 22, Nov. 18, 2011, 10 pages.
[cited by applicant]
Harker et al., “Cell-intrinsic Interleukin-27 and GP130 Cytokine Receptor Signaling Regulates Virus Specific CD4+ T cell Responses and Viral Control During Chronic Infection”, Immunity, vol. 39, No. 3, Sep. 19, 2013, 25…
[cited by applicant]
Harrop et al., “Antibodies to TR2 (Herpesvirus Entry Mediator), a New Member of the TNF Receptor Superfamily, Block T Cell Proliferation, Expression of Activation Markers, and Production of Cytokines”, The Journal of Im…
[cited by applicant]
Hernandez-Santos et al., “Th17 Cells in Immunity to Candida albicans”, Cell Host Microbe, vol. 11, No. 5, May 17, 2012, 21 pages.
[cited by applicant]
Hirahara et al., “Interleukin-27 Priming of T Cells Controls IL-17 Production in Trans Via Induction of the Ligand PD-1”, Immunity, vol. 36, No. 6, Jun. 29, 2012, 1017-1030.
[cited by applicant]
Hisada et al., “Potent Antitumor Activity of Interleukin-27”, Cancer Research, vol. 64, Feb. 1, 2004, 1152-1156.
[cited by applicant]
Hodi et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma”, The New England Journal of Medicine, vol. 363, No. 8, Aug. 19, 2010, 711-723.
[cited by applicant]
Howard et al., “RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System”, Molecular Therapy, vol. 14, No. 4, Oct. 2006, 476-484.
[cited by applicant]
Hsu et al., “Development and Applications of CRISPR-Cas9 for Genome Engineering”, Cell, vol. 157, No. 6, Jun. 5, 20314, 34 pages.
[cited by applicant]
Hsu et al., “DNA Targeting Specificity of RNA-Guided Cas9 Nucleases”, Nature Biotechnology, vol. 31, No. 9, Sep. 2013, 17 pages.
[cited by applicant]
Itoh et al., “Personalized Peptide Vaccines: A New Therapeutic Modality for Cancer”, Cancer Science, vol. 97, No. 10, Oct. 2010, 970-976.
[cited by applicant]
Jayaraman et al., “Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo”, Angewandte Chemie International Edition, vol. 51, 2012, 8529-8533.
[cited by applicant]
Zhu et al., “An IL-27/NFIL3 Signalling Axis Drives Tim-3 and IL-10 Expression and T-cell Dysfunction”, Nature Communications, vol. 6, No. 6072, Jan. 23, 2015, 11 pages.
[cited by applicant]
Uno et al., “High-Density Lipoprotein Facilitates In Vivo Delivery of Alpha-Tocopherol-Conjugated Short-Interfering RNA to the Brain”, Human Gene Therapy, vol. 22, Jun. 2011, 711-719.
[cited by applicant]
Van Der Maaten et al., “Visualizing Data Using t-SNE”, Journal of Machine Learning Research, vol. 9, Nov. 2008, 2579-2605.
[cited by applicant]
Verma et al., “Small Interfering RNAs Directed Against Beta-catenin Inhibit the in Vitro and in Vivo Growth of Colon Cancer Cells”, Clinical Cancer Research, vol. 9, No. 4, Apr. 2003, 1291-1300.
[cited by applicant]
Villarino et al., “The IL-27R (WSX-1) Is Required to Suppress T Cell Hyperactivity during Infection”, Immunity, vol. 19, Issue 5, Nov. 2003, 645-655.
[cited by applicant]
Vlad et al., “Immunoglobulin-Like Transcript 3-Fc Suppresses T-Cell Responses to Allogeneic Human Islet Transplants in hu-NOD/SCID Mice”, Diabetes, vol. 57, No. 7, Jul. 2008, 1878-1886.
[cited by applicant]
Von Essen et al., “Constitutive and Ligand-Induced TCR Degradation”, Journal of Immunology, vol. 173, No. 1, Jul. 1, 2004, 384-393.
[cited by applicant]
Wahlgren et al., “Plasma Exosomes can Deliver Exogenous Short Interfering RNA to Monocytes and Lymphocytes”, Nucleic Acids Research, vol. 40, No. 17, Sep. 1, 2012, 12 pages.
[cited by applicant]
Waite et al., “Th17 Response and Inflammatory Autoimmune Diseases”, International Journal of Inflammation, vol. 2012, Article ID 819467, 2012, 10 pages.
[cited by applicant]
Walte et al., “Multipeptide Immune Response To Cancer Vaccine IMA901 After Single-Dose Cyclophosphamide Associates with Longer Patient Survival”, Nature Medicine, vol. 18, No. 8, Aug. 2012, 12 pages.
[cited by applicant]
Wang et al., “CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity”, Cell, vol. 163, No. 6, Dec. 3, 2015, 1413-1427.
[cited by applicant]
Wang et al., “Genetic Screens in Human Cells Using the CRISPR/Cas9 System”, Science, vol. 343, No. 6166, Jan. 3, 2014, 12 pages.
[cited by applicant]
Wang et al., “One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering”, Cell, vol. 153, No. 4, May 9, 2013, 13 pages.
[cited by applicant]
Wang et al., “Stable and Controllable RNA Interference: Investigating the Physiological Function of Glutathionylated Actin”, Proceedings of the National Academy of Sciences of the United States of America, vol. 100, No.…
[cited by applicant]
Weintraub, Karen, “Biomedicine: The new gold standard”, Nature, vol. 495, Mar. 14, 2013, S14-S16.
[cited by applicant]
Wende et al., “The Transcription Factor c-Maf Controls Touch Receptor Development and Function”, Science, vol. 335, Issue 6074, 2012, 1373-1376.
[cited by applicant]
Wherry et al., “Molecular and Cellular Insights into T Cell Exhaustion”, Nature Reviews Immunology, vol. 15, No. 8, Aug. 2015, 29 pages.
[cited by applicant]
Wherry, Johne. , “T Cell Exhaustion”, Nature Immunology, vol. 12, No. 6, Jun. 2011, 492-499.
[cited by applicant]